| Literature DB >> 16054466 |
Keiichi Tsuchida1, Andrew T L Ong, Jiro Aoki, Carlos A G van Mieghem, Gastón A Rodriguez-Granillo, Marco Valgimigli, Georgios Sianos, Evelyn Regar, Eugène P McFadden, Willem J van der Giessen, Pim J de Feyter, Peter P T de Jaegere, Ron T van Domburg, Patrick W Serruys.
Abstract
The aim of this study was to evaluate the outcome after paclitaxel-eluting stent implantation in 40 patients with 52 saphenous vein graft lesions. By Kaplan-Meier estimates, the probability of major adverse cardiac event-free survival for 1 year was 92.5%. A paclitaxel-eluting stent for saphenous vein graft disease appears to be feasible and safe, with a low rate of reintervention at 1 year, but late follow-up is needed to confirm these observations.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16054466 DOI： 10.1016/j.amjcard.2005.03.084
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778